Federal Register Notice: FDA has determined the regulatory review period for Aegerion Pharmaceuticals’ Juxtapid (lomitapide mesylate) is 6,002 days for extending a patent which claims the human drug product. It is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. To view this notice, click here.